Lumonus, an AI-driven leader in radiation oncology workflow solutions, has closed a A$25 million Series B funding round led by Aviron Investment Management, with significant participation from Oncology Ventures.
This round aims to scale the clinical adoption of Lumonus’ AI platform, which is already integrated with health systems across the U.S., Australia, and Europe.
What is Lumonus?
Lumonus delivers an AI-native digital oncology platform that automates and orchestrates radiation oncology workflows.
Founded with a leadership team bringing over 100 years of combined clinical, operational, and ani, Lumonus focuses on improving cancer treatment quality and operational efficiency.
The platform supports clinicians by automating complex tasks such as treatment planning and prescription, enhancing both consistency and speed in cancer care delivery.
To date, Lumonus AI has aided in over 280,000 cancer treatments and generated more than 75,000 automated treatment plans.
Funding and Company Metrics
| Round | Date | Amount | Lead Investors | Notes |
|---|---|---|---|---|
| Series B | November 2025 | A$25 million | Aviron Investment Management | Scaling AI oncology workflows worldwide |
| Metric | Score / Note |
|---|---|
| Investor Profile | Experienced healthcare and technology investors |
| Team Expertise | Clinical, operational, and technical leaders |
| Product Impact | Automates 280K+ treatments, 75K+ plans generated |
| Market Potential | Modernizing clinical oncology workflows |
| AICURATOR Rating | 8.2/10 – Strong clinical adoption and growth |
Why This Series B Investment is Significant?
This funding round highlights growing confidence in AI to modernize oncology workflows, which have lagged behind advances in cancer treatment technologies.
CEO Keith Hansen emphasizes that while scientific breakthroughs in cancer care have surged, the systems supporting clinical teams remain outdated.
Lumonus combines AI-native design with an end-to-end workflow approach, collaborating closely with clinicians to solve real-world care challenges.
Aviron Investment Management’s leadership in this round reflects a strong belief in Lumonus’ potential to transform oncology systems globally.
Use of Funds and Growth Plans
The new capital will accelerate product innovation, expanding US go-to-market and clinical success teams.
Lumonus will enhance key products like Lumonus AI Physician and Lumonus AI Dosimetry, while investing in clinical informatics to improve the use of real-world evidence for better care personalization and operational performance.
Expansion efforts focus on increasing adoption in major health systems worldwide.
Key Deal Facts
What’s Next for Lumonus?
Lumonus is set to scale its commercial footprint in the U.S. and boost its product line to meet rising demand for AI-powered oncology solutions.
The company faces the challenge of integrating AI workflows into established clinical environments but benefits from strong investor backing and proven clinical impact.
Its steady traction in multiple regions positions it well for global expansion and setting new standards for oncology care workflows.
This funding underlines AI’s increasing role in health tech, especially in mission-critical areas like cancer treatment, marking Lumonus as a promising player in healthcare innovation.
Social Handles for Lumonus
| Platform | Handle / Link |
|---|---|
| linkedin.com/company/lumonus | |
| Website | lumonus.com |
| X (Twitter) | @lumonusoncology |
